Print Page | Contact Us | Sign In | JOIN FPA
FPA Midyear Nuclear Conference


Register Here!

For the Virtual CE Conference


 Registration Rates

Full Conference and One-Day registration do NOT include "Reducing Medication Errors" or "Human Trafficking" CE

***The add-on CE sessions will be held on Saturday October 3rd and Sunday October 4th***


Full Conference
$225 / $330

Single Day
$170 / $205


Registration + Membership




Full Conference
$55 / $75

Single Day
$45 / $65


Registration + Membership



Add-On CE:

Medication Errors

Saturday, October 3rd

 $30 / $40


Human Trafficking

Sunday, October 4th

 $30 / $40



 General CE Information

: Sessions begin at 9 am

Handouts will be made available the week of the meeting HERE

  • 12 contact hours offered for Nuclear Recertification or General CE

  • FPA automatically reports all CE credits to CEBroker and CPE Monitor

  • Florida Board Approved Required Courses


View brochure and session details


Claim CE Credit

Thursday (Oct 1) Attendance & Evaluation 
Friday (Oct 2) Attendance & Evaluation



Continuing Education Sessions

  Thursday Sessions

USP 825 Compliance – Hospital Perspective
Nic Mastascusa, PharmD, RPh, BCNP, Chief Nuclear Pharmacist, University of Iowa Hospitals and Clinics, Clinical Assistant Professor, University of Iowa College of Pharmacy

Nuclear Medicine Imaging with DMSA and Verification of DMSA Content in a Compounded Kit
Wendy Galbraith, PharmD, BCNP, Nuclear Pharmacy Education Coordinator, University of Oklahoma College of Pharmacy

Understanding NETS and the Role of Copper Cu 64 Dotatate Injection
Fred Gattas, PharmD, BCNP, FAPhA, Director of Medical and Safety Affairs-North America, Curium Pharma and Rhenee Robinson, PharmD, Medical Science Liaison, Curium Pharma

Updates in Prostate Imaging and Therapy
Ashley Mishoe, PharmD, Medical Science Liaison, Novartis


  Friday Sessions

The Role of Estrogen Receptor in Breast Cancer

Ross Weatherman , PhD, Professor, Rose– Hulman Institute of Technology

Nuclear Medicine and Breast Cancer
Kara Weatherman PharmD, BCNP, FAPhA, Clinical Associate Professor of Pharmacy Practice, Director, Nuclear Pharmacy Programs, Purdue University

Nuclear Medicine Pharmacy and Clinical Experience of 131I-Iobenguane for the Treatment of Pheochromocytoma and Paraganglioma
Dao Le, PharmD, BCNP, FAPhA, Director, Nuclear Medicine Radiopharmacy, Director, Cyclotron Radiochemistry Facility, The University of Texas, M.D. Anderson Cancer Center and Gera Santiago, Nuclear Medicine Technologist, UTMD Anderson Cancer Center

Novel Radiopharmaceuticals in Oncology: Current Status and Future Development
Hijin Angela Park, PharmD, RMIP Core Nuclear Pharmacist II, Radiochemistry & Molecular Imaging Probes Core

USP<825> Compliance in Commercial Radiopharmacies 
David Barnes, RPh, BCNP, RPD Pharmacy Operations, Global Supply Chain Life Sciences Core Imaging, GE Healthcare